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Background: Lung cancer in the United States is a substantial cause of mortality. 
According to the American College of Radiology’s Lung Cancer Screening Registry, 
only 1.9% of eligible patients were screened for lung cancer in 2016. The National 
Comprehensive Cancer Network and U.S. Preventative Services Task Force (USPSTF) 
guidelines recommend lung cancer screening (LCS) in high-risk patients. The USPSTF 
recommends screening current and former smokers aged 55-80 years who have smoked 
for 20 or more pack-years, and for former smokers, those that have quit within 15 years. 
Purpose: The primary purpose of the study is to determine if a questionnaire screening 
tool used in a primary care setting, will increase the number of referrals for lung cancer 
screening in patients with tobacco use disorder. 
Design Methods: This will be a descriptive, quality improvement practice intervention. 
Data will be collected before and after implementation of the project. 
Conclusion: Low-dose computed tomography (LDCT) lung cancer screening guidelines 
have not been widely implemented into national evidence-based clinical practice as 
evidenced by low national lung cancer screening rates. The primary care provider most 
often represents the initial point of coordination of preventative care and is a crucial link 
between the high-risk lung cancer patients and the LDCT screening center. While this 
single site quality improvement project did not show improvement in LDCT screening 
 
v 
referral rates, it does provide potentially useful data regarding referral rates in Northwest 
Georgia. 
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INCREASING LUNG CANCER SCREENING REFERRALS IN PATIENTS WITH 
TOBACCO USE DISORDER 
Introduction 
In the United States, lung cancer is the leading cause of cancer-related death 
regardless of ethnicity or gender. More than 50% of patients are diagnosed with advanced 
or incurable lung cancer at diagnosis. Individuals with Stage III and IV lung cancer have 
5-year relative survival rates of 5% and 1%, respectively (American Cancer Society 
[ACS], 2021). Tobacco smoking is the number one risk factor for lung cancer and has 
been linked to 80% to 90% of all lung cancer cases. Smokers age 55 and older, who have 
a minimum of a 20-pack year tobacco smoking history and currently smoke or have quit 
within the past 15 years, are at greatest risk for developing lung cancer (United States, 
2021). 
 The American College of Radiology’s Lung Cancer Screening Registry suggested 
that in 2016 only 1.9% of eligible patients had been screened. Compliance with lung 
cancer screening recommendations is a multifaceted issue and a potential limitation of 
lung cancer screening compliance is a lack of knowledge and awareness among primary 
care providers (Mukthinuthalapati et al., 2020).
Background 
 Lung cancer accounts for approximately 25% of cancer mortality in both men and 
women and is the leading cause of cancer-related death. (ACS, 2021).  The American 
Cancer Society's estimates for lung cancer in the United States for 2021 is 235,760 new 





will be diagnosed with lung and bronchus cancer during their lifetime (Howlander, et al., 
2017). 
As the data reveals, lung cancer is prevalent in the United States and is a 
significant cause of mortality. More people die each year of lung cancer than colon, 
breast, and prostate cancers combined (ACS, 2021). Unfortunately, once lung cancer 
symptoms arise, it is most likely an advanced stage. The average age of lung cancer 
diagnosis is 70 years (ACS, 2021). The lifetime risk that a man will develop lung cancer 
is 1 in 15 while, for a woman, the risk is about 1 in 17 (ACS, 2021). The 5-year relative 
cancer survival rate for non-small cell lung cancer is about 25% and for small cell lung 
cancer it is 7%. Approximately 56% of lung and bronchus cancers are diagnosed after 
they have metastasized to distant areas, and the 5-year relative survival rate is only 3% to 
7% at that point (ACS, 2021).     
 The National Comprehensive Cancer Network and U.S. Preventive Services Task 
Force (USPSTF) guidelines recommend annual lung cancer screening (LCS) in high-risk 
patients. These patients who are considered high risk meet the following guideline 
criteria: current and former smokers aged 55-80 years who have smoked for 20 or more 
pack-years and currently smoke or have quit within 15 years if a former smoker (Raz et 
al., 2016). LCS is a mandated benefit for non-Medicare plans under the Affordable Care 
Act and is approved by the Centers for Medicare Services for Medicare beneficiaries 
(Raz, et al., 2016). In addition, LCS with low dose computed tomography (LDCT) is 
recommended by several other professional societies, including the American Cancer 





(Fukunaga, Wiener & Slatore, 2021). Criteria used to determine eligibility are the same 
except for the age requirement. Patients with private health insurance are eligible for ages 
55-80, whereas, for Medicare, eligibility ages are 55-77. Screening with LDCT disclosed 
incidental findings including aortic aneurysms, coronary artery calcifications, and other 
lung findings such as emphysema, bronchiectasis, pulmonary fibrosis, and carcinoid 
tumors (Agency for Healthcare Research and Quality [AHRQ], 2016). 
Problem Statement 
Patients and healthcare providers must be informed of the potential benefits of 
annual LDCT screening to reach its full potential in reducing lung cancer mortality. 
However, two gaps must be filled: the educational gap and the coverage gap. The current 
problem is there is no standardized screening tool in place to ensure patients who meet 
the screening criteria are getting appropriate referrals (United States Preventive Services 
Taskforce [USPSTF], 2021). For many of these high-risk patients, fear is a driving factor 
of their willingness to participate in annual screenings, whether the fear is related to the 
possibility of receiving a cancer diagnosis or scared to seek medical treatment due to the 
presence of certain symptoms, and limit their involvement in lung cancer treatment and 
survivorship care (Hamann et al., 2018). This DNP project determined if a questionnaire 
increased the number of referrals made for annual lung cancer screening. The PICOT 
question for this project is: in patients with current or a history of tobacco use disorder, 
will implementation of the USPSTF lung cancer screening increase referrals compared to 





Organizational Description of Project Site  
The study took place at an internal medicine office in northwest Georgia, and is 
comprised of four physicians, one physician assistant, and one nurse practitioner. Primary 
care providers are an integral component in referring patients for necessary health 
screenings.   
Review of the Literature 
The United States Preventive Task Force officially recommended yearly LDCT 
screening for patients 55-80 with at least a 20 pack-year history who currently smoke or 
have quit smoking in the last 15 years, after the results of the National Lung Screening 
Trial (NLST) were released in 2011. This trial demonstrated a 20% reduction in mortality 
among patients who received LDCT screening (Okereke, Nishi, Zhou & Goodwin, 2019). 
Notably, LDCT is the first cancer screening test found to reduce overall mortality 
(USPSTF, 2021). More than 80% of patients with lung cancer are diagnosed at stage III 
due to the lack of screening (Okereke et al., 2019). 
Lung cancer has a poor overall prognosis, with a survival rate of only 18%, 5 
years after diagnosis (Okereke et al., 2019). Most lung cancer diagnoses are made in 
advanced stages which is associated with poor prognosis. LDCT screening aims to 
combat late detection by finding and diagnosing lung cancer at earlier stages. Lung 
cancer detected by LDCT screening will be discovered at an early stage 64% to 85% of 
the time (Okereke et al., 2019). Numerous trials and data demonstrate the efficacy of 
LDCT lung cancer screening but not using or implementing an effective screening 





of the NLST study were released, lung screening programs were created at numerous 
organizations across the country. However, implementation of these programs has not 
been widespread. Reports using the Behavioral Risk Factor Surveillance System 
(BRFSS) survey estimated that fewer than 5% of eligible patients receive LDCT 
screening (Okereke et al., 2019). From this study, Okereke and his colleagues show the 
rate of LDCT screening for each month in 2016 and 2017. The rate of screenings rose 
throughout 2016 and early 2017 and appeared to plateau by approximately July 2017. In 
the multivariate analysis, patients aged 60 to 69 had the highest rates, with those aged 55-
59 and 75-77 with the lowest rates. Women had 15% lower odds of receiving LDCT 
screening (Okereke et al., 2019). 
 A study from Jemal and Fedawa (2017), claimed there were 8.4 million people 
eligible for LDCT screening in 2010. Based off this statistic and considering the United 
States Census data, 13.2% of adults aged 55 to 77 years nationwide were eligible for 
LDCT screening. Other studies have shown similarly low rates of LDCT screening 
(Okereke et al., 2019). These low screening rates are well behind screening rates for 
prostate, breast, and colon cancer. It is understandable that it would take time for 
providers and the healthcare system to catch up to the recommendation of annual LDCT 
screening for the population of interest; however, since May 2017, data suggests there 
has been very little increase in screening rates (Jemal & Fedawa, 2017).  
 The youngest and oldest groups of eligible patients, those aged 55-59 and 75-77, 
had the lowest rates of LDCT screening. This could be because patients aged 55 to 59 




90% of smokers begin smoking by age 18 or younger, it is more likely that there is a 
larger percentage of eligible patients in this range, compared to other ages, who are not 
being screened (Okereke et al., 2019). A major reason for this trend may be a lack of 
awareness among this population. It is imperative to increase awareness in younger 
patients to increase the percentage of patients overall who receive appropriate LDCT 
screening. Approximately 12,000 patients between the ages of 55 to 59 die each year 
from lung cancer, so increasing screening in this age group is likely to have major impact 
in reducing overall lung cancer mortality (Okereke et al., 2019; Jemal & Fedawa, 2017). 
The negligible increase in LDCT screening rates after May 2017 suggests that 
further measures are required to improve screening rates. Lack of awareness by high-risk 
individuals can be improved with advertising by public health to promote the benefits of 
screening. It is imperative providers discuss this screening with patients who have a long 
smoking history but might not be 55 years of age. Smokers who see a primary care 
provider regularly would be more likely to undergo LDCT screening than smokers who 
do not frequent a doctor’s office.  
Barriers do exist as to why patients are either not being referred for the screening 
or decide to not be screened. However, data on these barriers is scant compared to other 
cancer screening studies such as mammography. Provider barriers to lung cancer 
screening include a lack of awareness regarding guidelines for LCS, lack of time to 
counsel patients regarding LCS, or misperceptions regarding the risks and benefits (Raz, 
et al., 2016). Primary care providers are the stewards of preventative healthcare, 





referring patients for LDCT and the providers’ perceptions on guidelines for, relative 
benefits of, and barriers to LCS. Possible system barriers include a lack of standardized 
methods for identifying patients eligible for LCS, availability to these centers offering 
LDCT, and low rates of smokers who have consistent follow-up with primary care 
providers.  
The National Cancer Institute funded the National Lung Screening Trial to 
determine whether screening with LDCT compared with chest radiography would reduce 
mortality from lung cancer among high-risk individuals. The participants were 
randomized and underwent either LDCT or chest x-ray annually for 3 screens. The NLST 
trial is the first randomized screening trial for lung cancer to have shown improvement in 
both disease-specific and all-cause mortality (Gutierrez, et al., 2013). The NLST was also 
the first trial to provide evidence to support screening for lung cancer with LDCT in 
reducing lung cancer deaths. This study randomized 53,454 high-risk individuals aged 55 
to 74 years to compare annual screenings with LDCT or standard chest x-rays and 
followed them for an average of 6.5 years. Patients were found to be 16 to 20% less 
likely to die of lung cancer when screened with LDCT versus standard chest radiographs, 
(AHRQ, 2016). This reduction in mortality is equivalent to preventing three lung cancer 
deaths per 1,000 people (AHRQ, 2016). Previous studies had shown that screening with 
standard chest x-rays does not reduce the mortality rate from lung cancer. 
 Data from the NLST trial suggests that 10 to 20% of lung carcinomas diagnosed 
by LDCT might have never been detected in the patient’s lifetime in the absence of 




screened to save one life from lung cancer. This estimate compares favorably with 
screening mammography, in which some estimates suggest that 465-601 women must be 
screened to save one life from breast cancer (Gutierrez et al., 2013). According to Goulart 
and Ramsey (2013), 18,000 lung cancer deaths could be prevented annually if LDCT 
lung cancer screening were implemented nationally. 
Early detection and diagnosis of lung cancer can subsequently reduce the 
morbidity and mortality rates associated with lung cancer. However, the risks versus the 
benefits on an individual patient basis must be weighed against the unintended harms and 
adverse effects of screening for persons exposed to LDCT who did not have lung cancer. 
This is why it is important for patients who meet USPSTF eligibility criteria to be 
routinely seen by their primary care providers, have discussions regarding the LDCT lung 
cancer screening, and when appropriate, be referred annually for screening and compliant 
with follow-up protocols. 
Evidence-Based Practice: Verification of Chosen Option 
Despite widespread recommendations, in the United States healthcare system, 
LDCT lung cancer screening remains inadequately implemented. (Lewis et al., 2019). 
Most lung cancer diagnoses, approximately 70%, are diagnosed at advanced stages when 
curative options are limited, which is why annual screening is so important in high-risk 
patients. The current 5-year survival rate is only 18% when lung cancer is detected in an 
advanced stage (Lewis et al., 2019). The National Lung Screening Trial found that annual 




mortality by 6.7% compared with annual chest radiographic screening in high-risk 
individuals (Lewis, et al., 2019). 
Theoretical Framework/Evidence-Based Practice Model 
 Nola Pender’s Health Promotion Model (HPM) uses behavioral science to explain 
and predict health behaviors (Pender & Pender, 1996). A diagram of the Health 
Promotion Model is included in Appendix A (Nola Pender, 2020). This model helps to 
identify the influences of biopsychosocial elements that may help engage patients in a 
particular health behavior to prevent or reduce the likelihood of negative health outcomes 
or improve current health status. The most common health behavior change that utilizes 
the HPM is exercise. The health-promoting behavior of interest, in this case, is lung 
cancer screening for lung cancer.  
 The actual and ideal behaviors must be addressed with any health behavior 
changes to determine the change that needs to take place. The HPM attempts to close the 
gap between the actual and ideal behaviors. The actual behavior for this project includes 
current heavy smoking or history of heavy smoking and the ideal behavior being not 
smoking. A person will be most likely to make positive health changes when they 
perceive the benefits of action or positive outcomes will occur from the health behavior 
change. The HPM is about getting to an ideal health status on an individual basis, not 
cure, which allows for this model to be applied to a wide variety of health behaviors.  
Within the behavioral outcome, a person commits to an achievable planned strategy that 
leads to the implementation of the health behavior of interest. When using the HPM, an 





achievable in terms of improvement. The person also self-determines if the expected 
benefit is important and attainable. A person also considers any obstacles in the path of 
the behavior change. If any obstacles exist, whether real or perceived, it is more likely the 
behavior will not be initiated. Other influences that may determine the likelihood of a 
successful behavior change include, but not limited to a person’s lifestyle, beliefs, and 
other social determinants of health (Pender & Pender, 1996).  
 There is a complex relationship between psychological variables such as stigma, 
mistrust, fear, and fatalism, and the constructs of the HBM, which allows healthcare 
providers to have a complete view of patients needing to undergo lung cancer screening 
(Carter-Harris, Davis & Rawl, 2016). Taking these patient beliefs and concerns into 
consideration is essential for adapting future interventions with this high-risk population. 
 Using the Health Promotion Model for lung cancer screening participation 
conceptualizes an individual’s willingness to participate in lung cancer screenings and 
addresses the psychological reasoning in one’s willingness to participate. The 
psychological variables are linked to the traditional HPM constructs that have predicted 
participation in screening for other cancers and the shared decision-making process. The 
decision to participate is influenced by psychological beliefs, demographic and health 
status characteristics, cognitive variables, receiving a healthcare provider 
recommendation, social and environmental variables, and personal beliefs regarding lung 




Objectives and Expected Outcomes 
The objectives of this DNP project were to (1) improve the process of identifying patients 
who meet the criteria for the lung cancer screening and (2) ensuring the referral was 
made when appropriate. The primary outcome was to measure improvement for LDCT 
screening referral of the eligible patients was determined by the responses given from the 
questionnaire and the appropriate referral was made. 
Project Design 
This project was a descriptive, quality improvement practice intervention. Data 
was collected before and during the implementation phase of the project to determine the 
number of referrals made before and during the implementation of the patient 
questionnaire. The Information Technology provided the de-identified data to determine 
the number of referrals made per month.  
Project Site and Population   
The target population is anyone who meets the following USPSTF lung cancer 
screening criteria. Adults between 55 and 80 years old who are at high risk for lung 
cancer due to being current heavy smokers or have quit within the past 15 years and have 
a 20-pack year smoking history, should be screened annually with a low-dose computed 
tomography scan. Inclusion criteria are the same guidelines for the lung cancer screening, 
which includes adults age 55-80 who currently smoke or have quit smoking in the past 15 
years, who have a 20-pack year smoking history. Exclusion criteria includes patients who 






Setting Facilitators and Barriers 
The Medical Assistants (MA) were crucial to the implementation as they provided 
patients the questionnaire when putting them in a room, if the patient met the age criteria 
of 55-80. The patient completed the questionnaire while waiting for the provider. The 
providers would review the questionnaire and determine if the patient is an appropriate 
candidate for the lung cancer screening and made the referral, if indicated.    
No obvious barriers existed to the implementation process other than resistance 
by providers to order the lung cancer screening when indicated or the screening was 
declined by the patient.  
Implementation Plan/Procedures 
The implementation of the project was vital although it was straightforward. The 
MA gave the patient a pen and questionnaire to complete while waiting for the provider if 
they were between the ages of 55 and 80. The provider will review the questionnaire and 
determine if the patient is a candidate for the screening based on their questionnaire 
responses. If the patient met the screening criteria and the patient was willing, a referral 
for the LDCT lung cancer screening was sent to the imaging department. The imaging 
department would then call the patient to schedule an appointment.  
The Information Technology department generated reports with the number of 
LDCT referrals that were ordered in a specific time frame. A report was generated for the 
2 months before implementation and a second report generated for the 1-month 
implementation period to determine if using the questionnaire increased the number of 




if there was a statistically significant relationship of increased LDCT referrals with the 
implementation of the questionnaire. The questionnaire is included in Appendix B and 
the consent is included in Appendix C. 
Measurement Instruments 
 To measure this DNP Project’s outcome, data was collected by reports generated 
from the IT department to determine if using the questionnaire increased the number of 
referrals sent for LDCT lung cancer screenings. The number of referrals made in the 2 
months before implementation was determined and compared with the number of 
referrals made during the implementation period. The questionnaire is in Appendix B and 
the informed consent is located in Appendix C.  
Data Collection Procedures  
 If the patient was eligible, the appropriate referral and follow-up was made. The 
number of new referrals sent with the questionnaire over one month was compared to the 
number of referrals made before implementation of the questionnaire.  
 This project was designed to aid the adoption of evidence-supported lung cancer 
screening into primary care clinical practice by incorporating a questionnaire screening 
tool to facilitate referrals. If the patient is eligible, the appropriate referral and follow-up 
was made. The number of referrals with the questionnaire over one month was compared 
to the number of referrals made before implementation of the questionnaire. 
 As lung cancer screening is complex, the review of the literature has emphasized 
that education of the provider is important in lung cancer screening and was provided 




session with providers was delivered as a refresher as to what the screening guidelines 
are. Patients were evaluated as they presented for a regularly scheduled appointment to 
represent a primary care office more closely without staff dedicated to a lung cancer 
screening program.  
 Before the MA would bring a patient into an exam room, they would notice the 
age of the patient to determine if they needed to give the patient a questionnaire regarding 
smoking history to complete while waiting on the provider. The information provided 
was reviewed with the patient to calculate the pack-year history and assess the patient’s 
risk for lung cancer, undergo smoking cessation counseling, if needed, and refer for 
LDCT screening if appropriate.  
The data was extracted by the Information Technology department, as they can 
determine the number of referrals sent in a specific time frame. No protected health 
information (PHI) was collected. As the information is anonymous, there was no way to 
determine retrospectively if the patient meets the screening criteria but declined the 
screening. Data was then entered into an Excel spreadsheet and sent to a statistician for 
analysis. After the one-month implementation period (March 8, 2021 through April 2, 
2021), the number of LDCT referrals were measured and compared to the number of 
referrals made prior to the questionnaire implementation. 
Data Analysis  
Descriptive statistics were used to analyze data regarding pre- and post-
implementation referrals for LDCT lung cancer screening in patients with tobacco use 





statistical significance as there were very few data points to interpret. Due to low referral 
rates pre- and post-implementation, there is no statistical significance that the 
questionnaire increased the number of referrals. There is a very low statistical 
significance of 12.9% that more than 3 referrals would be sent in 1 month due to the 
questionnaire screening tool.  
 The p-value for this data set is 0.242, meaning that there is a 24.2% chance that in 
any given month, there will be 3 or more referrals ordered, and therefore, did not increase 
the number of referrals during the implementation period.  
Results 
 Referrals for lung cancer screening were low at this primary practice. In the 2 
months pre-implementation, there was 3 referrals made the first month and 1 referral 
made the second month. Over the 1-month implementation period, 3 referrals were made. 
Factors identified as contributing to patients not being referred for LDCT screening 
include the lack of time providers feel they have to discuss this screening with the patient, 
patient declination or indecisiveness, pack-year history too short, or the patient had quit 
smoking longer than 15 years.   
Discussion 
The goal of the DNP quality improvement project was to improve lung cancer 
screening in patients who meet the USPSTF screening guidelines in a primary care 
practice. The process to improve screening included incorporating a questionnaire into 




Utilizing a LDCT screening tool may be challenging during a primary care visit 
but it is an important aspect of expanding clinician knowledge and changing clinician 
behavior. The short implementation period could have had a role in the lack of statistical 
significance (Li, Chung, Wei & Luft, 2018). National LDCT lung cancer screening rates 
are low at 1.9% in the general population (Pham, Bhandari, Oechsli, Pinkston, & 
Kloecker, 2020). There is currently no data on the estimated or actual numbers of lung 
cancer screenings in the Georgia general population for comparison. 
Recent debate has questioned if the current USPSTF lung cancer screening 
guidelines are too stringent to apply to African American adult smokers, suggesting that 
the guidelines may be too conservative for this specific population citing racial 
differences in smoking patterns (Aldrich et al., 2019). Suggestions for modification of the 
eligibility to 20 pack-years, as well as decreased the minimum age to begin consideration 
for LDCT lung cancer screening from the current 55 years to 50 years (Aldrich et al., 
2019).  
There may be a larger percentage of people who are patients at this primary care 
clinic who do not have any insurance coverage and therefore do not have the coverage for 
the LDCT screening as patients with insurance. Numerous patients also do not meet all 
the USPSTF guidelines. For example, a patient is 62 years old and has smoked since the 
age of 17 but has either stopped smoking numerous times during those years or smoked 
less than a pack of cigarettes per day, so he or she would not meet screening guidelines. It 




decline the screening during their appointment. These patients may call the office back 
after initially declining to request the referral but there is no way of tracking these add-on 
referrals if they took place after the implementation period.  
Due to the length of the conversation regarding lung cancer screening, it may be 
beneficial for patients to return to their primary care provider for a follow-up 
appointment to discuss the LDCT screening as well as allowing for adequate time to 
answer questions. Many patients still trust their primary healthcare providers’ 
recommendations; however, healthcare has evolved and promotes patient-centered care, 
which takes into consideration the patient’s values and beliefs regarding their care. The 
provider’s role is to educate and guide the patients to health and well-being while 
ultimately allowing them to make the final decision. Shared decision making is a crucial 
component of the HPM so it is also important that the risks versus benefits and 
comorbidities be discussed when determining if the patient should be screened for lung 
cancer.  
Cost-Benefit Analysis/Budget  
This project is extremely affordable for the DNP student and the organization. 
The only time involved was for the DNP student creating the questionnaire, the providers 
taking the extra 2-20 minutes to review the questionnaire answers, discuss the risks 
versus benefits of the LDCT with the patient, order the scan, and the time spent by the 
patient completing the scan. It will generally take 30 to 60 minutes to have CT scan 
completed with most of the time spent prepping the patient for the scan. No financial 




detection of lung cancer, in the long run, will be of financial benefit to the patient as well 
as improving quality of life and reducing morbidity and mortality.  
Timeline 
Project approval took place beginning mid-February with project implementation 
starting March 8, 2021 through April 2, 2021. The project timeline is located in Appendix 
E. Data collection occurred over those 4 weeks and then a report was generated to 
determine the number of LDCT lung cancer screening referrals made during the 
implementation period. This data was then given to a statistician for data analysis. 
Roughly 1 week was required for this analysis.  
Ethical Considerations/Protection of Human Subjects 
The Jacksonville State University Institutional Review Board (IRB) approval was 
obtained before initiating the DNP project. See Appendix F for the approval letter. Health 
Insurance and Portability Act standards were maintained throughout the project, 
protecting the patients’ right to privacy. There were no apparent risks to the patients 
participating in this project. All spreadsheets and electronic files were password protected 
to prevent unauthorized access. Proof of IRB approval is in Appendix F
Conclusion 
  LDCT lung cancer screening guidelines have not been widely implemented into 
national evidence-based clinical practice as evidenced by low national lung cancer 
screening rates (ACS, 2021). The primary care provider most often represents the initial 
point of coordination of preventative care and is a crucial link between the high-risk lung 
cancer patients and the LDCT screening center. Primary care providers are well-
 
19 
positioned to assist patients with decision-making for lung cancer screening 
interventions. However, the primary care setting needs system changes to facilitate this 
process. While this single site quality improvement project did not show improvement in 
LDCT screening referral rates, it does provide potentially useful data regarding referral 
rates in Northwest Georgia. 
The United States Preventive Task Force, among other organizations, support the 
use of annual LDCT lung cancer screening for high-risk current and former adult 
smokers. The decision to be screened should be a shared decision between the patient and 
healthcare provider. This DNP project was designed to increase rates of lung cancer 
screening referrals and ultimately reduce lung cancer mortality rates. Additional research 
needs to be conducted in order to find the best solution to effectively educate patients on 
the LDCT screening and healthcare providers on the guidelines in order to appropriately 
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Nola Pender’s Health Promotion Model 









Lung Cancer Screening Questionnaire 
 
 
1. Do you currently smoke cigarettes?       Yes   ☐  (only complete #1)    No  ☐     
How many packs per day (or number of cigarettes per day) do you smoke?    
_________packs per day 
 
How many years have you smoked? ________ years 
 
 
2. Do you have a history of smoking cigarettes?       Yes   ☐       No  ☐  (skip to the                                                                                                                                            
end)                                                                    
 
Did you smoke for 30 years or longer?       Yes   ☐       No  ☐ (skip to the 
end) 
 
Have you quit smoking in the last 15 years?     Yes   ☐       No  ☐  
 
 




















Consent form for Questionnaire  
 




• This study is designed to identify patients who meet screening criteria for lung 
cancer based on age and history of smoking cigarettes, and determine if there is 
an increase in referrals made for patients who meet the screening criteria. 
Participation in the study is anonymous. The primary investigator will be 
available to answer any questions you may have.  
How long will it take me to do this? 
• 5 minutes 
Are there any risks of participating in the study?   
• No risks to participating in the study. 
What are the benefits of participating in the study? 
• Creating better coordination to screen for lung cancer in patients who smoke 
cigarettes or have smoked for 30 years.  
• Early detection of lung cancer 
Who can I contact for information about this study? 
• Emily Thornberry, NP-C (762)-235-2330 
You are free to refuse to participate in this research project or to withdraw your 
consent and discontinue participation in the project at any time without penalty. 
***My return of this survey implies my consent to participate in this research and I 
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